Top Markets
Coin of the day
Venus Medtech (Hangzhou) Inc. Venus Medtech (Hangzhou) Inc.

Venus Medtech (Hangzhou) Inc.

2500
Hisse Senetlerindeki Sıralama #24714
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the... Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; Liwen RF, a radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People’s Republic of China.
Hisse Fiyatı
$0.13048475
Piyasa Değeri
$57.55M
Değişim (1 gün)
-1.92%
Değişim (1 yıl)
-77.88%
Ülke
CN
Ticaret Venus Medtech (Hangzhou) Inc. (2500)

Kategori

Venus Medtech (Hangzhou) Inc. (2500) için P/B oranı
2026 itibarıyla P/B oranı TTM: 0
Venus Medtech (Hangzhou) Inc. şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/B oranı (TTM) 0'dir. 2026 yılının sonunda şirketin P/B oranı 0 idi.
Venus Medtech (Hangzhou) Inc. için P/B oranı geçmişi 2026 - 2026 arası
Her yılın sonunda P/B oranı
Yıl P/B Oranı Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için P/B oranı